'
Supriya
Lifescience hosted a conference call on Aug 14, 2025. During the call, the
company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr.
Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial
Officer.
Key takeaways of the call
In Q1 FY26,
revenue declined on a YoY basis due to delays in the production, caused by
repair and maintenance work. However, management reaffirmed its guidance of
approximately 20% YoY revenue growth for FY26 and aims to achieve Rs 1,000
crore in revenue by FY27, with an EBITDA margin between 33% and 35%.
The company
expects H2 FY26 to be significantly stronger than H1 FY26. Management
attributes the revenue decline solely to production issues and does not
anticipate any demand-related challenges.
Growth is
expected to be driven by the introduction of new products and expansion into
newer therapies. Th...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Jan-2026)
Federal Bank
Healthy all-round performance
-
(17-Jan-2026)
Fedbank Financial Services
AUM growth accelerates to 17%, spreads improve
-
(17-Jan-2026)
Tech Mahindra
NP up 14.1% YoY to Rs 1122 crore in Q3FY2026
-
(17-Jan-2026)
Wipro
Revenue up 5.5% yoy to Rs 23555.8 crore in Q3FY2026
|
|